MARCH 27
Days
- :
Hrs
- :
Min
- :
Sec
ePoster Gallery
P468: Multiplex immunofluorescent characterization of inter-patient and intra-patient heterogeneity in multi-metastatic SDH-deficient GIST
Rachael Lowney MD
P469: Paraneoplastic Syndrome in Dedifferentiated Liposarcoma of the Retroperitoneum: an Under-Appreciated Clinical Scenario
Marco Fiore FACS, FEBS
Fondazione IRCCS Istituto Nazionale dei Tumori
P470: Performance of a second preoperative Inflammatory-Immunologic-Metabolic Biomarkers Score originally built for Lung Cancer to predict overall survival also in Primary Retroperitoneal Sarcoma
Marco Fiore FACS, FEBS
Fondazione IRCCS Istituto Nazionale dei Tumori
P471: Population-based experience of neoadjuvant treatment for patients with gastrointestinal stromal tumors (GIST)
Emily Heath
University of Calgary
P472: Preoperative Inflammatory Biomarkers Prognostic Index (IBPI) as a prognostic score in Extremity and Superficial Trunk Soft Tissue Sarcomas.
Marco Fiore FACS, FEBS
Fondazione IRCCS Istituto Nazionale dei Tumori
P473: Prognostic Indicators of Early Metastasis in Soft Tissue Sarcomas: The Impact of Sarculator in Patient StratificationSoft tissue sarcomas (STS) are rare tumors, representing 1-2% of all solid malignancies, with an incidence of 1.8 to 5 cases per 100,000 p
Dorian Yarih Garcia-Ortega MD, PhD
National Cancer Institute (Mexico)
P474: Wild type vs. non-wild type gastrointestinal stromal tumors of gastric and small bowel origin: are tumor-specific factors associated with overall survival?
Shruthi Perati MD
Rutgers Robert Wood Johnson Medical School
P475: Management for N2-positive Non-small Cell Lung Cancer in the Military Health System
Andrew Marthy MD
Albany Medical Center
P476: Mediastinal Lymph Node Positivity in Patients Undergoing Robotic Esophagectomy
Maren Thomas MS
P478: Turning the Clock Back : Seven Year Experience of Pulmonary Metastatectomy from a Single Centre
John Alapatt MS (General surgery), DrNB (Surgical Oncology), FEBS, MRCS (Edinburgh)
MVR CANCER CENTRE AND RESEARCH INSTITUTE
P479: Understanding the “new normal”: A thematic analysis of patient and caregiver perspectives on challenges faced in recovery after esophagectomy
Steven Tohmasi MD, MPHS
Washington University School of Medicine
P480: Clinicopathologic and prognostic significance of biomarker expression in gastric cancer in a predominately Hispanic population
Ashley Montgomery DO
Mays Cancer Center, University of Texas Health San Antonio
P481: Factors Associated with Surgery Refusal in Patients with Stage I-III Esophageal Cancer and Their Effect on Survival
Luke Guy
Medical College of Georgia
P482: Gastric Cancer among California*s Hispanic Population: Highlighting Epidemiological Disparities
Amir Ashraf Ganjouei
University of California San Francisco
P483: Gastric Cancer in the United States: How Can We Do Better?
Gregory Sigler MD
P484: Impact of Lymph Node Ratio in Patients with Esophageal Cancer
Parker Wilson
P485: Intensive versus Standard Neoadjuvant 5-Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Gastric Cancer: A Retrospective Analysis
Josh Kim BA
Icahn School of Medicine at Mount Sinai
P486: Intermediate-term Mortality for Esophagogastric Malignancy: Implications for Shared Decision Making?
Andrew Folkerts MD
University of Chicago